Dabigatran Etexilate Mesylate CAS NO 872728-81-9 Inquire about Dabigatran Etexilate Mesylate

Tecoland supplies Dabigatran Etexilate Mesylate bulk active pharmaceutical ingredient (API) to the pharmaceutical industry. Our Dabigatran Etexilate Mesylate is manufactured by cGMP compliant facility. Welcome to contact us for further details including current DMF status for the product and up to date regulatory status of the manufacturing facility. We look forward to assisting you with your research and development projects.

Description

Dabigatran Etexilate Mesylate is an orally available mesylate salt form of the etexilate prodrug of dabigatran, a benzimidazole and direct thrombin inhibitor with anticoagulant activity. Upon administration, dabigatran etexilate is hydrolyzed by esterases and is converted into dabigatran. Dabigatran reversibly binds to and inhibits the activity of thrombin, a serine protease that converts fibrinogen into fibrin. This disrupts the coagulation cascade and inhibits the formation of blood clots.

A THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation.

Disclaimer:

Information on this page is provided for general information purposes. You should not make a clinical treatment decision based on information contained in this page without consulting other references including the package insert of the drug, textbooks and where relevant, expert opinion. We cannot be held responsible for any errors you make in administering drugs mentioned on this page, nor for use of any erroneous information contained on this page.